| Systematic (IUPAC) name | |
|---|---|
| (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
| Clinical data | |
| Trade names | Vantin |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a698024 |
| Pregnancy cat. | B1(AU) B(US) |
| Legal status | ℞-only (US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Protein binding | 21% to 29% |
| Metabolism | Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver |
| Half-life | 2 hours |
| Excretion | Renal, unchanged |
| Identifiers | |
| CAS number | 82619-04-3 |
| ATC code | J01DD13 |
| PubChem | CID 6335986 |
| DrugBank | DB01416 |
| ChemSpider | 4891496 |
| UNII | 7R4F94TVGY |
| KEGG | D07650 |
| ChEBI | CHEBI:3504 |
| ChEMBL | CHEMBL1672 |
| Chemical data | |
| Formula | C15H17N5O6S2 |
| Mol. mass | 427.458 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Cefpodoxime is an oral third generation cephalosporin antibiotic. It is marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin. It is active against most Gram positive and Gram negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.
Pfizer, the parent company of Pharmacia & Upjohn, markets cefpodoxime proxetil under the trade name Simplicef for veterinary use. The dose range in dogs is 5–10 mg/kg body weight, administered orally, once a day.